This Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Nontuberculous Mycobacteria (NTM) Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12-18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.
Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria (NTM) Infections.
This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RHB 204: RedHill Biopharma
RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine. The drug is in Phase III development for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections caused by Mycobacterium avium Complex (MAC). RHB-204 was granted both FDA Orphan Drug Designation for the treatment of NTM disease and QIDP Designation under the Generating Antibiotic Incentives Now Act (GAIN Act).
MAT2501: Matinas BioPharma
MAT2501 is an orally-administered Lipid Nano-Crystal formulation of the gram-negative antibiotic agent, amikacin. The drug is in Phase I clinical development for the treatment of Nontuberculous Mycobacteria (NTM) Infections. As a broad-spectrum aminoglycoside, amikacin is highly effective in treating a range of chronic and acute bacterial infections, including Non-Tuberculous Mycobacterium (NTM) infections. FDA designated MAT2501 as a QIDP and Orphan Drug for the treatment of NTM infections.
There are approx. 14+ key companies which are developing the therapies for Nontuberculous Mycobacteria (NTM) Infections. The companies which have their Nontuberculous Mycobacteria (NTM) Infections drug candidates in the most advanced stage, i.e. Phase III include, RedHill Biopharma.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.
Research Programme: mycobacterial disease therapeutics
Geography Covered
- Global coverage
Nontuberculous Mycobacteria (NTM) Infections Understanding
Nontuberculous Mycobacteria (NTM) Infections: Overview
Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12-18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.
Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria (NTM) Infections.
Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs Chapters
This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs
RHB 204: RedHill Biopharma
RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine. The drug is in Phase III development for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections caused by Mycobacterium avium Complex (MAC). RHB-204 was granted both FDA Orphan Drug Designation for the treatment of NTM disease and QIDP Designation under the Generating Antibiotic Incentives Now Act (GAIN Act).
MAT2501: Matinas BioPharma
MAT2501 is an orally-administered Lipid Nano-Crystal formulation of the gram-negative antibiotic agent, amikacin. The drug is in Phase I clinical development for the treatment of Nontuberculous Mycobacteria (NTM) Infections. As a broad-spectrum aminoglycoside, amikacin is highly effective in treating a range of chronic and acute bacterial infections, including Non-Tuberculous Mycobacterium (NTM) infections. FDA designated MAT2501 as a QIDP and Orphan Drug for the treatment of NTM infections.
Nontuberculous Mycobacteria (NTM) Infections: Therapeutic Assessment
This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Nontuberculous Mycobacteria (NTM) Infections
There are approx. 14+ key companies which are developing the therapies for Nontuberculous Mycobacteria (NTM) Infections. The companies which have their Nontuberculous Mycobacteria (NTM) Infections drug candidates in the most advanced stage, i.e. Phase III include, RedHill Biopharma.
Phases
This report covers around 14+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Nontuberculous Mycobacteria (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Nontuberculous Mycobacteria (NTM) Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.
Nontuberculous Mycobacteria (NTM) Infections Report Insights
- Nontuberculous Mycobacteria (NTM) Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Nontuberculous Mycobacteria (NTM) Infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nontuberculous Mycobacteria (NTM) Infections drugs?
- How many Nontuberculous Mycobacteria (NTM) Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nontuberculous Mycobacteria (NTM) Infections?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacteria (NTM) Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nontuberculous Mycobacteria (NTM) Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- RedHill Biopharma
- Janssen Pharmaceutical
- Spero Therapeutics
- Revimmune
- Matinas BioPharma
- MannKind Corporation
- Spero Therapeutics
- Shionogi
- Crestone
Key Products
- RHB 204
- Bedaquiline
- SPR 720
- CYT107
- MAT2501
- MNKD-10
- SPR-719
Research Programme: mycobacterial disease therapeutics
- MmpL3 inhibitor
Table of Contents
IntroductionExecutive Summary
Nontuberculous Mycobacteria (NTM) Infections: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Nontuberculous Mycobacteria (NTM) Infections - Analytical Perspective
In-depth Commercial Assessment
- Nontuberculous Mycobacteria (NTM) Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nontuberculous Mycobacteria (NTM) Infections Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
RHB 204: RedHill Biopharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
CYT107: Revimmune
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
MAT2501: Matinas BioPharma
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
MNKD-10: MannKind Corporation
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Nontuberculous Mycobacteria (NTM) Infections Key Products
Nontuberculous Mycobacteria (NTM) Infections- Unmet Needs
Nontuberculous Mycobacteria (NTM) Infections- Market Drivers and Barriers
Nontuberculous Mycobacteria (NTM) Infections- Future Perspectives and Conclusion
Nontuberculous Mycobacteria (NTM) Infections Analyst Views
Nontuberculous Mycobacteria (NTM) Infections Key Companies
AppendixList of Tables
Table 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- RedHill Biopharma
- Janssen Pharmaceutical
- Spero Therapeutics
- Revimmune
- Matinas BioPharma
- MannKind Corporation
- Spero Therapeutics
- Shionogi
- Crestone
